Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listCinacalcet hydrochloride

Cinacalcet hydrochloride

Synonym(s):AMG 073 hydrochloride;KRN 1493 hydrochloride;N-[1-(R)-(-)-(1-naphthyl)ethyl]-3-[3(trifluoromethyl)phenyl]-1-aminopropane hydrochloride;NPS 1493 hydrochloride

  • CAS NO.:364782-34-3
  • Empirical Formula: C22H23ClF3N
  • Molecular Weight: 393.88
  • MDL number: MFCD08067750
  • EINECS: 620-490-5
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Cinacalcet hydrochloride Structural

What is Cinacalcet hydrochloride?

Description

Cinacalcet is the first entry in a new class of therapeutic agents called the calcimimetics. It was launched as an oral treatment for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease on dialysis and for hypercalcemia in patients with parathyroid carcinoma. SHPT is associated with increased parathyroid hormone (PTH) secretion, which is triggered by low serum levels of calcium resulting from the failure of the kidney to clear phosphorous from the body and its inability to produce sufficient quantities of vitamin D. The consequences of increased PTH include stimulation of osteoclastic activity, cortical bone resorption and marrow fibrosis. PTH secretion is primarily regulated by the calcium-sensing receptor (CaR), which is located on the surface of the chief cell of the parathyroid gland. Calcimimetics bind to CaR and increase the sensitivity of CaR to extracellular calcium, thereby enabling its activation at subnormal levels of serum calcium. As a result, in the presence of these agents, the low levels of endogenous calcium in patients with renal failure are able to exert a suppressive effect on PTH secretion. Parathyroid carcinoma is also associated with elevated PTH levels, which are driven by autonomous parathyroid gland activity and subsequently lead to hypercalcemia. Although surgical resection is the primary therapy for treating hypercalcemia in parathyroid carcinoma patients, calcimimetics offer a nonsurgical alternative for patients with failed parathyroidectomy, metastatic parathyroid carcinoma, or high surgical risk. The recommended dosage of cinacalcet for the treatment of SHPT in chronic kidney disease is 30mg once daily at start and subsequent titration to 60, 90, 120 or 180 mg once daily. The dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma is 30 mg twice daily at start and subsequent titration to 60 or 90 mg twice daily, or 90mg three or four times daily as necessary to normalize serum calcium level. After oral administration of cinacalcet, maximum plasma concentration is achieved in approximately 2 to 6 hours. It has a terminal half-life of 30 to 40 hours and steady-state drug levels are reached within 7 days. Cinacalcet has a high volume of distribution (1000 L) and high protein binding (93%–97%). It is extensively metabolized in the liver, mainly by CYP3A4, CYP2D6 and CYP1A2. The primary routes of elimination are in the urine (80%) and in the feces (15%). In Phase III clinical trials involving 1136 patients with SHPT, administration of cinacalcet at 30–180 mg/day doses for 6 months produced 38–48% decrease in intact PTH. Overall, 64% of patients given cinacalcet achieved at least a 30% reduction in PTH, versus 11% of placebo patients. Calcium-phosphorous product was reduced 14% by the active treatment and did not change in the placebo group. In a much smaller clinical study involving 21 hypercalcemic patients with parathyroid carcinoma, administration of 60–360 mg/day doses of cinacalcet resulted in 71% of patients achieving a target reduction of ≥1 mg/dL in serum calcium. The most common adverse events in these trials were nausea and vomiting. In vitro, cinacalcet is a strong inhibitor of CYP2D6; therefore, dose adjustments may be required when coadministered with medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g. flecainide, vinblastine, thioridazine and most tricyclic antidepressants). Cinacalcet is prepared in a two-step synthesis starting from 3-[3-(trifluoromethyl)phenyl]propionaldehyde, by first condensing with (R)-(1-naphthyl)ethylamine to form the corresponding imine and subsequent reduction of the imine with sodium cyanoborohydride.

Chemical properties

Off-White to Tan Solid

Originator

NPS pharmaceuticals (US)

The Uses of Cinacalcet hydrochloride

Cinacalcet hydrochloride can be used in clinical trial in secondary hyperparathyroidism.

The Uses of Cinacalcet hydrochloride

Cinacalcet hydrochloride is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.

What are the applications of Application

Cinacalcet Hydrochloride is an allosteric activator of CaSR

Definition

ChEBI: A hydrochloride derived from equimolar amounts of cinacalcet and hydrogen chloride.

brand name

Sensipar (Amgen).

Biological Activity

Cinacalcet hydrochloride is a calcium-sensing receptor (CaSR) allosteric agonist. Activates CaSR signaling in cellular proliferation and phosphatidylinositol (PI) hydrolysis assays. Reduces serum parathyroid hormone levels in rats. Also potent CYP2D2 inhibitor (IC50 = 87 nM) and L-type calcium channel blocker. Orally bioavailable.

Mechanism of action

Cinacalcet hydrochloride directly regulates a major regulator of parathyroid hormone (PTH) secretion, the calcium-sensitive receptor (CaR) on parathyroid master cells. Cinacalcet hydrochloride reduces circulating levels of PTH by increasing the sensitivity of the CaR to extracellular calcium.

Side Effects

Cinacalcet hydrochloride was generally well tolerated in clinical trials. The severity of most treatment-emergent adverse events was mild to moderate. Common side effects of Cinacalcet hydrochloride include: nausea, vomiting, or unusual tiredness. Severe may also include low calcium levels in the blood, numbness/tingling of the skin; severe muscle cramps, seizures, and abnormal heartbeat.

Synthesis

General syntheses of this class of compounds have been published, however, the specific synthesis of cinacalcet (III) has not been available to date. The synthesis of cinacalcet, based on a patented procedure, is depicted in Scheme 3. A mixture of 1-acetonaphthone (21), 3-trifluoromethyl-1-propylamine (22) and titanium (IV) isopropoxide were stirred at rt to form the enamine intermediate which was reduced with methanolic sodium cyanoborohydride at rt to give corresponding racemic a-methyl amine (23). Compound 23 was resolved and then treated with HCl etherate to give cinacalcet hydrochloride (III) as a white solid.

Synthesis_364782-34-3

storage

Store at -20°C

References

[1] ureña p1, frazão jm. calcimimetic agents: review and perspectives. kidney int suppl. 2003 jun;(85):s91-6.
[2] colloton m1, shatzen e, wiemann b, starnes c, scully s, henley c, martin d.cinacalcet attenuates hypercalcemia observed in mice bearing either rice h-500 leydig cell or c26-dct colon tumors. eur j pharmacol. 2013 jul 15;712(1-3):8-15.

Properties of Cinacalcet hydrochloride

Melting point: 175-177°C
storage temp.  Inert atmosphere,2-8°C
solubility  insoluble in H2O; ≥17.85 mg/mL in DMSO; ≥56 mg/mL in EtOH
form  solid
color  White to off-white
InChI InChI=1/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/s3
CAS DataBase Reference 364782-34-3(CAS DataBase Reference)

Safety information for Cinacalcet hydrochloride

Signal word Danger
Pictogram(s)
ghs
Corrosion
Corrosives
GHS05
ghs
Exclamation Mark
Irritant
GHS07
ghs
Health Hazard
GHS08
GHS Hazard Statements H302:Acute toxicity,oral
H314:Skin corrosion/irritation
H317:Sensitisation, Skin
H373:Specific target organ toxicity, repeated exposure
H413:Hazardous to the aquatic environment, long-term hazard
Precautionary Statement Codes P260:Do not breathe dust/fume/gas/mist/vapours/spray.
P273:Avoid release to the environment.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P314:Get medical advice/attention if you feel unwell.
P303+P361+P353:IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Computed Descriptors for Cinacalcet hydrochloride

InChIKey QANQWUQOEJZMLL-LSQUZMQTNA-N
SMILES C12C=CC=CC1=CC=CC=2[C@@H](C)NCCCC1=CC=CC(C(F)(F)F)=C1.Cl |&1:10,r|

Abamectin manufacturer

Piramal Pharma Solutions

1Y
Phone:+91-9892735994
Whatsapp: +91 9892735994
product: Cinacalcet hydrochloride 99%
Inquiry

Cipla Ltd

1Y
Phone:+912224826000
product: Cinacalcet hydrochloride 364782-34-3 98%
Inquiry

Hetero Drugs Limited

1Y
Phone:+914023704923
product: 364782-34-3 Cinacalcet hydrochloride 98%
Inquiry

Macleods Pharmaceuticals Limited

1Y
Phone:+912266762800
product: 364782-34-3 98%
Inquiry

Vivimed Labs Ltd

1Y
Phone:+91-4066086608
product: Cinacalcet hydrochloride 98%
Inquiry

Unichem Laboratories Ltd

1Y
Phone:+91-2266888333
product: Cinacalcet hydrochloride 364782-34-3 98%
Inquiry

HRV Global Life Sciences

1Y
Phone:+91-9820219686
Whatsapp: +91 9820219686
product: 364782-34-3 Cinacalcet hydrochloride 99%
Inquiry

Aruvi Labs

1Y
Phone:+91-8056181939
Whatsapp: +91-8056181939
product: 364782-34-3 98%
Inquiry

Megafine Pharma

1Y
Phone:+91-9867686666
Whatsapp: +91 9867686666
product: Dabigatran etexilate mesylate 99%
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.